Summary
The key focus for 3Q FY12/2026 is when revenue recovers. The "TissueBlue™" license agreement with DORC expired in December 2025. As a result, 1H revenue was only JPY 33M, consisting solely of royalties on "GLA-ALPHA® Combination Ophthalmic Solution." Hitting the full-year plan of JPY 300M depends on securing a contract extension and resuming royalty recognition. On the cost side, R&D restraint held the 1H operating loss roughly flat YoY. The open question is how much non-clinical studies for "H-1337," now refocused on development in Japan, will lift costs from 2H onward. On the pipeline, we will track progress in the data analysis for the "K-321" Phase III trials. Preparations for the US launch of "Bondlido," slated for 4Q 2026, are another key driver of corporate value.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Revenue RecoveryStatus of the "TissueBlue™" contract extension and 3Q cumulative revenue progress against the full-year plan | 1H revenue was JPY 33M, or 11.0% of the full-year plan of JPY 300M (our estimate). The gap versus the prior-year 3Q cumulative figure of JPY 297M will show whether royalties have resumed. |
Cost ControlQuarterly R&D expense trend and 3Q cumulative operating loss YoY | 1H R&D expenses were JPY 217M (-31.7% YoY). Backing out from the full-year plan, the implied 2H operating loss is JPY -468M (our estimate), wider than the 1H loss of JPY -312M. The timing and nature of the cost increase are therefore key. |
Pipeline ValueProgress in data analysis for the "K-321" global Phase III trials and Kowa's next-stage plans | The observation periods for both trials ended in March 2026. K-321 carries no milestone income, so monetization is limited to post-launch royalties. There is no impact on 3Q P&L. |
Development & Launch PreparationProgress in "H-1337" development in Japan and launch preparations for "Bondlido" | H-1337 development in Japan has been prioritized following the option agreement with Senju Pharmaceutical covering Japan and Asia. Bondlido is slated for launch in 4Q 2026, so any revenue contribution will appear from the full-year (4Q) results onward. |
Financial BaseCash and cash equivalents, restricted deposits, and borrowings at 3Q-end | Cash and cash equivalents stood at JPY 986M at 1H-end, with a separate JPY 595M placed in restricted deposits. 1H operating CF was JPY -343M. We will track the cash position alongside progress on fundraising. |
Key Issues from Previous Results (FY12/2026 2Q Results)
For 1H FY12/2026, revenue was JPY 33M (-80.9% YoY) and the operating loss was JPY 312M (vs. an operating loss of JPY 309M in the prior-year period). "TissueBlue™" royalties were temporarily suspended, but R&D restraint kept the loss in line with the prior year. The company maintained its full-year plan (revenue of JPY 300M; recurring loss of JPY 800M). The two focal points for 3Q are the resumption of royalties and the pace of development spending.
1. "TissueBlue™" Royalty Resumption and Visibility on the Full-Year Revenue Plan
- Previous Quarter: The license agreement with DORC expired in December 2025. Talks on an extension are ongoing for regions where patents remain in force, so 1H revenue of JPY 33M includes no TissueBlue™ royalties.
- This Quarter's Checkpoints: We want to confirm the timing and terms of an extension agreement. The company expects to book royalties as revenue based on the agreed terms, making 3Q recognition a key point.
- Key Metrics: We will compare 3Q cumulative revenue with the prior-year figure of JPY 297M. We will also check progress against the full-year plan of JPY 300M (11.0% as of 1H, our estimate).
2. R&D Expense Trend and Progress Against the Loss Plan
- Previous Quarter: SG&A was JPY 346M (-25.5% YoY). R&D expenses fell to JPY 217M (-31.7% YoY) on lower development costs for H-1337 and DWR-2206. Other expenses declined to JPY 128M (-12.1% YoY) on lower personnel costs.
- This Quarter's Checkpoints: The 1H recurring loss was JPY 322M against a full-year plan of JPY 800M. We will check whether 2H costs rise due to non-clinical studies ahead of H-1337 clinical trials in Japan (hypothesis).
- Key Metrics: We will watch standalone 3Q R&D spending and the 3Q cumulative recurring loss. Progress on the recurring loss against the full-year plan was 40.3% as of 1H, versus 50.2% of the full-year actual in the prior-year period (both our estimates).
3. Progress in "K-321" Global Phase III Data Analysis
- Previous Quarter: Of the two ongoing global Phase III trials, the observation period for the remaining trial ended in March. With observation periods complete for all trials, data analysis is underway.
- This Quarter's Checkpoints: We want to confirm the progress of the analysis and the filing plans of licensee Kowa. K-321 carries no milestone income, and post-launch royalties are the company's only revenue source from the asset.
- Key Metrics: We will review K-321's development-stage designation and the description of analysis status in the earnings materials. Assuming no contribution to 3Q P&L, we will assess its role as a medium- to long-term earnings base.
4. "H-1337" Development in Japan and "Bondlido" Launch Preparation
- Previous Quarter: In March, the company signed an option agreement with Senju Pharmaceutical covering Japan, Asia, and other regions for H-1337. It received a JPY 194M equity investment from Senju and shifted to prioritizing development in Japan. For Bondlido, co-development partner MEDRx and Terrain Pharmaceuticals agreed on basic terms for a US commercialization partnership in May.
- This Quarter's Checkpoints: For H-1337, we will check progress in non-clinical studies ahead of clinical trials in Japan. For Bondlido, we will check the status of a definitive commercialization license agreement. The launch is slated for 4Q 2026, so any revenue contribution is an item for the full-year (4Q) results onward.
- Key Metrics: We will review H-1337's development-stage designation in the pipeline chart and any disclosure of a Bondlido agreement. We will also monitor the supplies balance (JPY 128M at 1H-end, +JPY 41M vs. prior FY-end), though its link to launch preparations needs to be confirmed with the company.
5. Cash Position and Fundraising Progress
- Previous Quarter: Cash and cash equivalents were JPY 986M (-JPY 723M vs. prior FY-end). Investing CF was JPY -601M due to the placement of JPY 595M in restricted deposits. Financing CF was +JPY 222M, driven by JPY 194M from a new share issuance and JPY 49M from the exercise of stock acquisition rights.
- This Quarter's Checkpoints: The company states it has "secured sufficient funds for business activities for the time being," while also considering new financing as needed. We will check the use and release conditions of the restricted deposits, as well as fundraising progress during 3Q.
- Key Metrics: We will check cash and deposits at 3Q-end (JPY 1.654B at the prior-year 3Q-end). We will also track the long-term borrowings balance (JPY 583M at 1H-end, including the current portion) and net assets.
Key Timely Disclosures During the Quarter
- 2026/10/01Completion of Payment for the 14th Series Stock Acquisition Rights (With Exercise Price Adjustment Clause) and 2nd Series Unsecured Bonds via Third-Party Allotment - This financing was resolved on September 14. The bonds total JPY 500M, and proceeds are earmarked for H-1337 development. Payment came after the 3Q period-end, so it is not reflected in the 3Q balance sheet and will be an item for the full-year (4Q) results. Given the exercise price adjustment clause, we also want to monitor future exercise activity and the pace of dilution.
- 2026/09/30US Commercialization Partnership and Launch Timing for "Bondlido" - The expected signing of the exclusive commercialization license agreement with Terrain Pharmaceuticals was revised to within 2026, while the 4Q 2026 launch target was maintained. Expected sales volume now looks set to exceed initial assumptions, prompting a review of sales strategy, supply plans, and contract terms. Any revenue contribution will appear from the full-year (4Q) results onward.
Previous Quarter Results (FY12/2026 2Q Actual)
The company is a drug discovery venture that creates new drug candidates in ophthalmology, centered on protein kinase inhibitors. Its business model is to license out development assets to pharmaceutical companies in exchange for royalties and other income. It has two marketed products: Kowa's "GLA-ALPHA® Combination Ophthalmic Solution" and DORC's "TissueBlue™." Its development pipeline includes "K-321," licensed out to Kowa; the in-house asset "H-1337"; and "Bondlido," co-developed with MEDRx. The earnings release contains no medium-term management plan with numerical targets. In 1H, revenue fell 80.9% YoY, but SG&A cuts kept the operating loss in line with the prior year.
| Item | Amount | YoY | vs. Company Plan | Notes |
|---|---|---|---|---|
| Revenue | JPY 33M | -80.9% | 11.0% Progress | GLA-ALPHA® only; no TissueBlue™ revenue booked as extension talks are ongoing |
| Operating Income | JPY -312M | - | 40.0% Progress | Prior-year period JPY -309M; R&D expenses JPY 217M (-31.7%) |
| Recurring Profit | JPY -322M | - | 40.3% Progress | Prior-year period JPY -316M; JPY 4M in share issuance costs booked |
| Net Income | JPY -323M | - | 40.4% Progress | Prior-year period JPY -316M; no extraordinary items |
| EPS | JPY -5.80 | - | 39.3% Progress | Prior-year period JPY -7.08; loss per share narrowed on higher average shares outstanding |
(All figures in the "vs. Company Plan" column are progress rates against the full-year plan, based on our estimates.)
Guidance Achievement Rate (Recurring Profit Basis): 40.3% (prior-year period: 50.2%, vs. full-year actual)
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.